Related Experiment Video
Updated: Jul 13, 2025
Models of Bone Metastasis
Published on: September 4, 2012
Wnt1 induces osteoblastic changes in a well-established osteolytic skeletal metastatic model derived from breast
Aya Sugyo1, Atsushi B Tsuji1, Hitomi Sudo1
1Experimental Nuclear Medicine Group, Department of Molecular Imaging and Theranostics, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan.
Background:
Osteoblastic skeletal metastasis is frequently observed in prostate cancer. An effective therapy has not been developed due to the unclear molecular mechanism. The Wnt family is involved in various biological phenomena including bone metabolism. There is no direct evidence that the family causes osteoblastic skeletal metastasis.
Aims:
The present study aims to evaluate whether overexpressed Wnt induces osteoblastic bone metastasis in a well-established osteolytic bone metastatic model.
Methods And Results:
The breast cancer-derived 5a-D-Luc-ZsGreen cells were transfected with Wnt1, Wnt3A, and Wnt5A expression vectors, producing stably highly expressing cells. These cells were intracardially transplanted in nude mice. Bone metastasis development was confirmed by fluorescence imaging. Hind-limb bones including metastasis were dissected and visualized through micro-CT imaging. After imaging, sections were stained with hematoxylin and eosin (H&E), and immunohistochemically stained with an anti-SATB2 antibody. Luminescent imaging confirmed mice with bone metastases in the hind limbs. Micro-CT imaging found an osteoblastic change only in bone metastasis of mice transplanted with Wnt1-expressing cells. This was confirmed on H&E-stained sections. SATB2 immunostaining showed differentiated osteoblasts were at the site of bone metastases in the diaphysis. SATB2 in the Wnt/β-catenin pathway activated by overexpressed Wnt1 could induce osteoblastic change.
Conclusion:
Our findings provided direct evidence Wnt1 is involved in osteoblastic bone metastasis development. Our model would be a powerful tool for further elucidating molecular mechanisms underlying the disease and developing effective therapies.
Insights
Wnt1 overexpression drives osteoblastic bone metastasis in prostate cancer, offering a new therapeutic target. This study reveals Wnt1
Area of Science:
- Oncology
- Bone Metastasis Research
- Molecular Biology
Background:
- Osteoblastic skeletal metastasis is common in prostate cancer.
- The molecular mechanisms driving this process remain unclear.
- The Wnt family's role in bone metabolism is known, but its direct link to osteoblastic metastasis is unproven.
Purpose of the Study:
- To investigate if Wnt overexpression induces osteoblastic bone metastasis.
- To utilize a well-established osteolytic bone metastatic model for evaluation.
Main Methods:
- Breast cancer cells engineered to overexpress Wnt1, Wnt3A, or Wnt5A were used.
- Cells were intracardially transplanted into nude mice.
- Bone metastasis was assessed using fluorescence imaging, micro-CT, H&E staining, and SATB2 immunohistochemistry.
Main Results:
- Wnt1-expressing cells led to osteoblastic changes in bone metastases, confirmed by micro-CT and H&E staining.
- SATB2 immunostaining indicated differentiated osteoblasts at metastatic sites.
- Wnt1, via the Wnt/β-catenin pathway, was identified as a driver of osteoblastic change.
Conclusions:
- Direct evidence links Wnt1 to the development of osteoblastic bone metastasis.
- The developed model serves as a valuable tool for future research into disease mechanisms and therapy development.
More Related Videos
06:00Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
Published on: September 13, 2017
07:00Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
Published on: September 26, 2016
Related Concept Videos
02:54Canonical Wnt Signaling Pathway
01:41Non-Canonical Wnt Signaling Pathways
01:31Osteoclasts in Bone Remodeling